Savara to Present at JMP Securities 2018 Life Sciences Conference on June 20th
June 13, 2018 08:00 ET
|
Savara
AUSTIN, Texas, June 13, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, announced today that the company's Chief Executive Officer, Rob Neville, will present at...
Savara Provides Update on Case Reports of Inhaled Granulocyte-Macrophage Colony Stimulating Factor for the Treatment of Nontuberculous Mycobacteria Infection
May 29, 2018 08:00 ET
|
Savara
AUSTIN, Texas, May 29, 2018 (GLOBE NEWSWIRE) -- Savara, Inc. (NASDAQ:SVRA), an orphan lung disease company, today provided an update on two case reports exploring the use of aerosolized...
UPDATE -- Savara to Present at Bank of America Merrill Lynch 2018 Healthcare Conference on May 15th
May 15, 2018 12:26 ET
|
Savara
AUSTIN, Texas, May 15, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, announced today that the Company's Chief Executive Officer, Rob Neville, will present at...
Savara to Present at Bank of America Merrill Lynch 2018 Healthcare Conference on May 17th
May 11, 2018 08:00 ET
|
Savara
AUSTIN, Texas, May 11, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, announced today that the Company's Chief Executive Officer, Rob Neville, will present at...
Savara Reports First Quarter 2018 Financial Results and Provides Business Update
May 09, 2018 16:02 ET
|
Savara
Molgradex Phase 3 IMPALA study enrollment on track for completion in Q3 2018AeroVanc Phase 3 AVAIL study enrollment on track for completion in Q1 2019Molgradex Phase 2a OPTIMA study enrollment on...